ArticleRenal failure2025
Intermedin prevents acute heart failure following acute kidney injury by alleviating inflammatory responses.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Current Application Prospects of Nanomedicine in Renal Ischemia-Reperfusion Injury.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute heart failure (AHF) is a common complication of acute kidney injury (AKI), which leads to a poor prognosis in AKI patients. The pathogenesis of AHF is closely related to cardiac inflammatory responses. Intermedin (IMD) has been demonstrated to attenuate cardiac inflammation, however, its role in AHF following AKI (AKI-AHF) remains to be elucidated. We aimed to investigate the effects of IMD on AKI-AHF and to elucidate the underlying mechanisms. We demonstrated that AKI induced by bilateral kidney ischemia-reperfusion injury (IRI) upregulated IMD and its receptors in the kidneys and heart. Following kidney IRI, AHF was more severe in IMD knockout (IMD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.